J-STAGE トップ  >  資料トップ  > 書誌事項

臨床薬理
Vol. 42 (2011) No. 6 P 369-373

記事言語:

http://doi.org/10.3999/jscpt.42.369

特集/プロトンポンプ阻害薬と抗血小板薬クロピドグレル,プラスグレルの最近の話題

Clopidogrel is an antiplatelet drug that is used in patients who have had previous cerebrovascular events, acute coronary syndromes, or percutaneous coronary interventions (PCI). Clopidogrel therapy is associated with bleeding complications, and gastrointestinal bleeding has been reported as one of the most common life-threatening complications. This review focuses on the possible interaction between clopidogrel and CYP2C19, a known site of PPI metabolism. This interaction attenuates the antiplatelet effect of clopidogrel and seems to worsen cardiovascular outcome. Alternative concomitant therapy is also discussed.

Copyright © 2011 日本臨床薬理学会

この記事を共有